1. Can the pharmaceutical industry reduce attrition rates?;Kola;Nat. Rev. Drug Discov.,2004
2. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?;Laverty;Br. J. Pharmacol.,2011
3. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative – update on progress;Colatsky;J. Pharmacol. Toxicol. Methods,2016
4. The potential role of the J-T peak interval in proarrhythmic cardiac safety: current state of the science from the American College of Clinical Pharmacology and the Cardiac Safety Research Consortium;Vicente;J. Clin. Pharmacol.,2019
5. Automated algorithm for J-T peak and T peak-tend assessment of drug-induced proarrhythmia risk;Johannesen;PLoS One,2016